Genetic polymorphisms in MDR1 and CYP3A4 genes in Asians and the influence of MDR1 haplotypes on cyclosporin disposition in heart transplant recipients

Pharmacogenetics

Volumn 13, Issue 2, 2003, Pages 89-95

  Chowbay, Balram ^a   Cumaraswamy, Sivathasan ^b   Cheung, Yin Bun ^b   Zhou, Qingyu ^b   Lee, Edmund J D ^b  

^a DIVISION OF MEDICAL ONCOLOGY   (Singapore)

^b NONE

Author keywords

Asian population; Cyclosporine A; CYP3A4; Ethnicity; MDR1; P glycoprotein; Pharmacokinetics

Indexed keywords

CYCLOSPORIN A; CYTOCHROME P450 3A4; MULTIDRUG RESISTANCE PROTEIN 1;

AREA UNDER THE CURVE; ARTICLE; ASIAN; CHINESE; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG DISPOSITION; ETHNIC DIFFERENCE; ETHNIC GROUP; EXON; GENE FREQUENCY; GENE MUTATION; GENETIC POLYMORPHISM; HAPLOTYPE; HEART TRANSPLANTATION; HOMOZYGOSITY; HUMAN; INDIAN; NUCLEOTIDE SEQUENCE; POLYMORPHIC LOCUS; PRIORITY JOURNAL; PROMOTER REGION; RECIPIENT;

ADMINISTRATION, ORAL; AREA UNDER CURVE; ASIA; CYCLOSPORINE; CYTOCHROME P-450 ENZYME SYSTEM; DNA PRIMERS; ETHNIC GROUPS; EXONS; GENE FREQUENCY; GENES, MDR; GENETIC PREDISPOSITION TO DISEASE; HAPLOTYPES; HEART TRANSPLANTATION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MIDDLE AGED; POLYMERASE CHAIN REACTION; POLYMORPHISM, GENETIC; PROMOTER REGIONS (GENETICS);

EID: 0037330517     PISSN: 0960314X     EISSN: None     Source Type: Journal    
DOI: 10.1097/00008571-200302000-00005     Document Type: Article

References (22)

1. Chen CJ, Chin JE, Ueda K, Clark DP, Pastan I, Gottesman MM, et al. Internal duplication and homology with bacterial transport proteins in the mdr1 (P-glycoprotein) gene from multidrug-resistant human cells. Cell 1986; 47:381-389.
2. Ambudkar SV, Dey S, Hrycyna CA, Ramachandra M, Pastan I, Gottesman MM. Biochemical, cellular and pharmacological aspects of the multidrug transporter. Annu Rev Pharmacol Toxicol 1999; 39:361-398.
3. Hoffmeyer S, Burk O, von Richter O, Arnold, Brockmoller J, Johne A, et al. Functional polymorphisms of the human multi-drug resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo. Proc Natl Acad Sci USA 2000; 97:3473-3478.
4. Cascorbi I, Gerloff T, Johne A, Miesel C, Hoffmeyer S, Schwab M, et al. Frequency of single nucleotide polymorphisms in the P-glycoprotein drug transporter MDR1 gene in white subjects. Clin Pharmacol Ther 2001; 69:169-174.
5. Ameyaw MM, Regateiro F, Li T, Liu X, Tariq M, Mobarek A, et al. MDR1 pharmacogenetics: frequency of the C3435T mutation in exon 26 is significantly influenced by ethnicity. Pharmacogenetics 2001; 11:217-221.
6. Schaeffeler E, Eichelbaum M, Brinkmann U, Penger A, Asante-Poku S, Zanger UM, et al. Frequency of the C3435T polymorphism of MDR1 gene in African people. Lancet 2001; 358:383-384.
7. Kim RB, Leake BF, Choo EF, Dresser GK, Kubba SV, Schwarz UI, et al. Identification of functionally variant MDR1 alleles among European Americans and African Americans. Clin Pharmacol Ther 2001; 70:189-199.
8. Sakaeda T, Nakamura T, Horinouchi M, Kakumoto M, Ohmoto N, Sakai T, et al. MDR1 genotype-related pharmacokinetics of digoxin after single oral administration in healthy Japanese subjects. Pharm Res 2001; 18:1400-1404.
9. Tanabe M, Ieiri I, Nagata N, Inoue Kazuko, Ito Soichiro, Kanamori Y, et al. Expression of P-glycoprotein in human placenta: relation to genetic polymorphism of the multidrug resistance (MDR)-1 gene. J Pharmacol Exp Ther 2001; 297:1137-1143.
10. Rebbeck TR, Jaffe JM, Walker AH, Wein AJ, Malkowicz SB. Modification of clinical presentation of prostate tumours by a novel genetic variant in CYP3A4. J Natl Cancer Inst 1998; 90:1225-1229.
11. Ball SE, Scatina J, Kao J, Ferron GM, Fruncillo R, Mayer P, et al. Population distribution and effects on drug metabolism of a genetic variant in the 5′ promoter region of CYP3A4. Clin Pharmacol Ther 1999; 66:288-294.
12. Walker AH, Jaffe JM, Gunasegaram S, Cummings SA, Huang CS, Chern HD, et al. Characterization of an allelic variant in the nifedipine-specific element of CYP3A4: ethnic distribution and implications for prostate cancer risk. Hum Mutat 1998; 12:289:1998.
13. Sata F, Sapone A, Elizondo G, Stocker P, Miller VP, Zheng W, et al. CYP3A4 allelic variants with amino acid substitutions in exons 7 and 12: evidence for an allelic variant with altered catalytic activity. Clin Pharmacol Ther 2000; 67:48-56.
14. Hsieh KP, Lin YY, Cheng CL, Lai ML, Lin MS, Siest JP, Huang JD. Novel mutations of CYP3A4 in Chinese. Drug Metab Dispos 2001; 29:268-273.
15. Saeki T, Ueda K, Tanigawara Y, Hori R, Komano T. Human P-glycoprotein transports cyclosporin A and FK506. J Biol Chem 1993; 268:6077-6080.
16. Lown KS, Mayo RR, Leichtman AB, Hsiao HL, Turgeon DK, Schmiedlin-Ren P, et al. Role of intestinal P-glycoprotein (mdr) in interpatient variation in the oral bioavailability of cyclosporine. Clin Pharmacol Ther 1997; 62:248-260.
17. Sham PC. Statistics in human genetics. London: Arnold; 1998.
18. Mander A. Haplotype frequency estimation using an EM algorithm and log-linear modelling. Stata Tech Buff Reprints 2001; 10:104-107.
19. Ito S, Ieiri I, Tanabe M, Suzuki A, Higuchi S, Otsubo K. Polymorphisms of the ABC transporter genes, MDR1, MRP1 and MR2P/cMOAT, in healthy Japanese subjects. Pharmacogenetics 2001; 11:175-184.
20. Stein CM, Sadeque AJ, Murray JJ, Wandel C, Kim RB, Wood AJJ. Cyclosporine pharmacokinetics and pharmacodynamics in African American and white subjects. Clin Pharmacol Ther 2001; 69:317-323.
21. Kim RB, Fromm MF, Wandel C, Leake B, Wood AJ, Roden DM, et al. The drug transporter P-glycoprotein limits oral absorption and brain entry of HIV-1 protease inhibitors. J Clin Invest 1998; 101:289-294.
22. Goto M, Masuda S, Saito H, Uemoto S, Kiuchi T, Tanaka T, et al. C3435T polymorphism in the MDR1 gene affects the enterocyte expression level of CYP3A4 rather than P-gp in recipients of living-donor liver transplantation. Pharmacogenetics 2002; 12:451-457.